Cargando…
Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients
Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG‐degrading enzyme of Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single‐center, open‐label ascending‐dose study in highly sensitized patients with chronic kidney disease. Eight patients with cytotoxic PRAs (median cyt...
Autores principales: | Lorant, Tomas, Bengtsson, Mats, Eich, Torsten, Eriksson, Britt‐Marie, Winstedt, Lena, Järnum, Sofia, Stenberg, Yvonne, Robertson, Anna‐Karin, Mosén, Kristina, Björck, Lars, Bäckman, Lars, Larsson, Erik, Wood, Kathryn, Tufveson, Gunnar, Kjellman, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221156/ https://www.ncbi.nlm.nih.gov/pubmed/29561066 http://dx.doi.org/10.1111/ajt.14733 |
Ejemplares similares
-
Imlifidase-generated Single-cleaved IgG: Implications for Transplantation
por: Bockermann, Robert, et al.
Publicado: (2021) -
Streptococcus pyogenes Infection and the Human Proteome with a Special Focus on the Immunoglobulin G-cleaving Enzyme IdeS
por: Karlsson, Christofer A. Q., et al.
Publicado: (2018) -
Imlifidase for the treatment of anti‐HLA antibody‐mediated processes in kidney transplantation
por: Huang, Edmund, et al.
Publicado: (2021) -
Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)
por: Jordan, Stanley C., et al.
Publicado: (2021) -
Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity
por: Winstedt, Lena, et al.
Publicado: (2015)